Abstract
Colorectal cancer (CRC) is one of the most disseminated diseases across the globe engaging the digestive system. Various therapeutic methods from traditional to the state-of-the-art ones have been applied in CRC patients, however, the attempts have been unfortunate to lead to a definite cure. MiRNAs are a smart group of non-coding RNAs having the capabilities of regulating and controlling coding genes. By utilizing this stock-in-trade biomolecules, not only disease’s symptoms can be eliminated, there may also be a good chance for the complete cure of the disease in the near future. Herein, we provide a comprehensive review delineating the therapeutic relationship between miRNAs and CRC. To this, various clinical aspects of miRNAs which act as a tumor suppressor and/or an oncogene, their underlying cellular processes and clinical outcomes, and, in particular, their effects and expression level changes in patients treated with chemo- and radiotherapy are discussed. Finally, based on the results deducted from scientific research studies, therapeutic opportunities based on targeting/utilizing miRNAs in the preclinical as well as clinical settings are highlighted.
Highlights
Colorectal cancer (CRC) is one of the most prevalent gastrointestinal malignancies across the world, with over 1.2 million newly reported cases of this disease each year
Various therapeutic methods from traditional to the state-of-the-art ones have been applied in CRC patients, the attempts have been unfortunate to lead to a definite cure
Various clinical aspects of miRNAs which act as a tumor suppressor and/or an oncogene, their underlying cellular processes and clinical outcomes, and, in particular, their effects and expression level changes in patients treated with chemo- and radiotherapy are discussed
Summary
Roles of miRNAs in Colorectal Cancer: Therapeutic Implications and Clinical Opportunities. Amir Mehrgou[1] ID , Shima Ebadollahi[2], Khaled Seidi[3], Mohammad Hosein Ayoubi-Joshaghani[4,5], Amirhossein Ahmadieh Yazdi[6], Peyman Zare[7,8], Mehdi Jaymand9*, Rana Jahanban-Esfahlan10,11*. Article info Article History: Received: 28 Feb. 2020 Revised: 3 May 2020 Accepted: 26 July 2020 epublished: 26 July 2020
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
